The international dermatology outcome measures initiative as applied to psoriatic disease outcomes: A report from the GRAPPA 2013 meeting

Alice B. Gottlieb, April W. Armstrong, Robin Christensen, Amit Garg, Kristina Callis Duffin, Wolf Henning Boehncke, Joseph F. Merola, Dafna D. Gladman, Philip J. Mease, Robert A. Swerlick, Cheryl F. Rosen, April Abernethy

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

In the United States, access to care is the number one issue facing our patients with dermatological conditions. In part, this is because we do not have outcome measures that are useful in clinical practice and available in databases where payers and governmental agencies can compare the performance of physicians and treatments. There is a growing recognition that insufficient attention has been paid to the outcomes measured in clinical trials and subsequently in clinical practice. The International Dermatology Outcome Measures group includes all willing stakeholders: patients, physicians, payers, and pharmaceutical scientists. As reported herein, the group's goal is to develop outcome measures in dermatology that address the needs of all involved.

Original languageEnglish (US)
Pages (from-to)1227-1229
Number of pages3
JournalJournal of Rheumatology
Volume41
Issue number6
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Dermatology
Outcome Assessment (Health Care)
Physicians
Clinical Trials
Databases
Pharmaceutical Preparations
Therapeutics

Keywords

  • International dermatology outcome measures
  • National psoriasis foundation
  • Omeract
  • Outcome measures
  • Psoriasis

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy
  • Medicine(all)

Cite this

Gottlieb, A. B., Armstrong, A. W., Christensen, R., Garg, A., Duffin, K. C., Boehncke, W. H., ... Abernethy, A. (2014). The international dermatology outcome measures initiative as applied to psoriatic disease outcomes: A report from the GRAPPA 2013 meeting. Journal of Rheumatology, 41(6), 1227-1229. https://doi.org/10.3899/jrheum.140176

The international dermatology outcome measures initiative as applied to psoriatic disease outcomes : A report from the GRAPPA 2013 meeting. / Gottlieb, Alice B.; Armstrong, April W.; Christensen, Robin; Garg, Amit; Duffin, Kristina Callis; Boehncke, Wolf Henning; Merola, Joseph F.; Gladman, Dafna D.; Mease, Philip J.; Swerlick, Robert A.; Rosen, Cheryl F.; Abernethy, April.

In: Journal of Rheumatology, Vol. 41, No. 6, 2014, p. 1227-1229.

Research output: Contribution to journalArticle

Gottlieb, AB, Armstrong, AW, Christensen, R, Garg, A, Duffin, KC, Boehncke, WH, Merola, JF, Gladman, DD, Mease, PJ, Swerlick, RA, Rosen, CF & Abernethy, A 2014, 'The international dermatology outcome measures initiative as applied to psoriatic disease outcomes: A report from the GRAPPA 2013 meeting', Journal of Rheumatology, vol. 41, no. 6, pp. 1227-1229. https://doi.org/10.3899/jrheum.140176
Gottlieb, Alice B. ; Armstrong, April W. ; Christensen, Robin ; Garg, Amit ; Duffin, Kristina Callis ; Boehncke, Wolf Henning ; Merola, Joseph F. ; Gladman, Dafna D. ; Mease, Philip J. ; Swerlick, Robert A. ; Rosen, Cheryl F. ; Abernethy, April. / The international dermatology outcome measures initiative as applied to psoriatic disease outcomes : A report from the GRAPPA 2013 meeting. In: Journal of Rheumatology. 2014 ; Vol. 41, No. 6. pp. 1227-1229.
@article{4f3ed6d5cc5f479a8c28c5dd360d6bea,
title = "The international dermatology outcome measures initiative as applied to psoriatic disease outcomes: A report from the GRAPPA 2013 meeting",
abstract = "In the United States, access to care is the number one issue facing our patients with dermatological conditions. In part, this is because we do not have outcome measures that are useful in clinical practice and available in databases where payers and governmental agencies can compare the performance of physicians and treatments. There is a growing recognition that insufficient attention has been paid to the outcomes measured in clinical trials and subsequently in clinical practice. The International Dermatology Outcome Measures group includes all willing stakeholders: patients, physicians, payers, and pharmaceutical scientists. As reported herein, the group's goal is to develop outcome measures in dermatology that address the needs of all involved.",
keywords = "International dermatology outcome measures, National psoriasis foundation, Omeract, Outcome measures, Psoriasis",
author = "Gottlieb, {Alice B.} and Armstrong, {April W.} and Robin Christensen and Amit Garg and Duffin, {Kristina Callis} and Boehncke, {Wolf Henning} and Merola, {Joseph F.} and Gladman, {Dafna D.} and Mease, {Philip J.} and Swerlick, {Robert A.} and Rosen, {Cheryl F.} and April Abernethy",
year = "2014",
doi = "10.3899/jrheum.140176",
language = "English (US)",
volume = "41",
pages = "1227--1229",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "6",

}

TY - JOUR

T1 - The international dermatology outcome measures initiative as applied to psoriatic disease outcomes

T2 - A report from the GRAPPA 2013 meeting

AU - Gottlieb, Alice B.

AU - Armstrong, April W.

AU - Christensen, Robin

AU - Garg, Amit

AU - Duffin, Kristina Callis

AU - Boehncke, Wolf Henning

AU - Merola, Joseph F.

AU - Gladman, Dafna D.

AU - Mease, Philip J.

AU - Swerlick, Robert A.

AU - Rosen, Cheryl F.

AU - Abernethy, April

PY - 2014

Y1 - 2014

N2 - In the United States, access to care is the number one issue facing our patients with dermatological conditions. In part, this is because we do not have outcome measures that are useful in clinical practice and available in databases where payers and governmental agencies can compare the performance of physicians and treatments. There is a growing recognition that insufficient attention has been paid to the outcomes measured in clinical trials and subsequently in clinical practice. The International Dermatology Outcome Measures group includes all willing stakeholders: patients, physicians, payers, and pharmaceutical scientists. As reported herein, the group's goal is to develop outcome measures in dermatology that address the needs of all involved.

AB - In the United States, access to care is the number one issue facing our patients with dermatological conditions. In part, this is because we do not have outcome measures that are useful in clinical practice and available in databases where payers and governmental agencies can compare the performance of physicians and treatments. There is a growing recognition that insufficient attention has been paid to the outcomes measured in clinical trials and subsequently in clinical practice. The International Dermatology Outcome Measures group includes all willing stakeholders: patients, physicians, payers, and pharmaceutical scientists. As reported herein, the group's goal is to develop outcome measures in dermatology that address the needs of all involved.

KW - International dermatology outcome measures

KW - National psoriasis foundation

KW - Omeract

KW - Outcome measures

KW - Psoriasis

UR - http://www.scopus.com/inward/record.url?scp=84901698972&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901698972&partnerID=8YFLogxK

U2 - 10.3899/jrheum.140176

DO - 10.3899/jrheum.140176

M3 - Article

C2 - 24882858

AN - SCOPUS:84901698972

VL - 41

SP - 1227

EP - 1229

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 6

ER -